Press Releases

Press Releases

  • Prometic announces share consolidation

    Prometic announces share consolidation

    Prometic is pleased to announce that the consolidation of the Corporation’s issued and outstanding common shares on the basis of one post-consolidation Common Share for every one thousand

    Read Article
  • Prometic announces voting results of its 2019 AGM

    Prometic announces voting results of its 2019 AGM

    Prometic announced the voting results from its 2019 Annual General and Special Meeting of Shareholders (“AGM”) held in Montreal, Quebec

    Read Article
  • Prometic announces completion of equity rights offering

    Prometic announces completion of equity rights offering

    Prometic is pleased to confirm the completion of its previously announced equity rights offering, raising aggregate gross proceeds of C$37,998,000 (or the equivalent of US$ 28,357,000)

    Read Article
  • Prometic presents new data on PBI-4050 and its mechanism of action on kidney fibrosis at the 56th ERA/EDTA congress

    Prometic presents new data on PBI-4050 and its mechanism of action on kidney fibrosis at the 56th ERA/EDTA congress

    Prometic presents new data on PBI-4050 and its mechanism of action on kidney fibrosis at the 56th fibrosis at the 56th ERA/EDTA congress

    Read Article
  • Prometic Life Sciences to present at two upcoming June investor conferences

    Prometic Life Sciences to present at two upcoming June investor conferences

    Prometic Life Sciences to present at two upcoming June investor conferences

    Read Article
  • Prometic presents new PBI-4050 and Ryplazim (plasminogen) data on long fibrosis at the 2019 ATS conference

    Prometic presents new PBI-4050 and Ryplazim (plasminogen) data on long fibrosis at the 2019 ATS conference

    Prometic today announced the presentation of three scientific posters on the Company’s lead small molecule and plasma-derived drug product candidates, respectively PBI-4050 and Ryplazim™.

    Read Article
  • Prometic announces terms of equity rights offering

    Prometic announces terms of equity rights offering

    Prometic is pleased to confirm the terms of its previously announced equity rights offering for gross proceeds of up to $75,000,000.

    Read Article
  • Prometic reports its 2019 first quarter financial results

    Prometic reports its 2019 first quarter financial results

    We made excellent progress during the quarter towards completing the necessary development work to permit re-filing of our Ryplazim™ (plasminogen) (“RyplazimTM ”) BLA before the end of 2019

    Read Article
  • Prometic strengthens its leadership with a new management structure and the appointment of three new directors

    Prometic strengthens its leadership with a new management structure and the appointment of three new directors

    Prometic is pleased to announce today a new management structure to provide leadership to the Corporation and the appointment of Dr. Gary Bridger, Mr. Timothy Wach and Mr. Neil Klompas to the Board.

    Read Article
  • Prometic Completes Refinancing Transactions Including C$75 Million

    Prometic Completes Refinancing Transactions Including C$75 Million

    Prometic is also pleased to announce Kenneth Galbraith as Chief Executive Officer.

    Read Article
  • Prometic announces refinancing transactions

    Prometic announces refinancing transactions

    Prometic announced today its intention to enter into a series of related arrangements to restructure Prometic’s outstanding indebtedness, reduce its interest and certain other payment obligations.

    Read Article
  • Prometic reports fourth quarter and 2018 year-end financial results

    Prometic reports fourth quarter and 2018 year-end financial results

    Total revenues for 2018 of $47.4 million compared to $39.1 million in 2017 and significant increase in bioseparation 2018 revenues to $22.7 million, a 35% increase over 2017

    Read Article
  • Prometic to report its fourth quarter and 2018 year-end financial results and hold conference call / webcast

    Prometic to report its fourth quarter and 2018 year-end financial results and hold conference call / webcast

    Prometic announced today that it will report its financial results for the fourth quarter and year ended December 31, 2018 on Monday April 1, 2019 after market close.

    Read Article
  • Prometic secures additional USD 5 million (CAD 6.7 million) tranche from Structured Alpha LP

    Prometic secures additional USD 5 million (CAD 6.7 million) tranche from Structured Alpha LP

    Prometic secures additional USD 5 million (CAD 6.7 million) tranche from Structured Alpha LP

    Read Article
  • Prometic secures additional USD $10 million (CAD $13.2 million) tranche from structured Alpha LP, an affiliate of Thomvest asset management

    Prometic secures additional USD $10 million (CAD $13.2 million) tranche from structured Alpha LP, an affiliate of Thomvest asset management

    Prometic announced today that it has secured an additional USD $10 million (CAD $13.2 million) tranche from Structured Alpha LP (“SALP”), an affiliate of Thomvest Asset Management Inc.

    Read Article
  • Prometic retains investment bank for strategic transactions

    Prometic retains investment bank for strategic transactions

    Prometic announced that it has engaged Lazard to review and execute key strategic transactions for the Corporation.

    Read Article
  • Prof. Simon Best appointed interim CEO of Prometic Life Sciences

    Prof. Simon Best appointed interim CEO of Prometic Life Sciences

    Prometic announced today that it has named Prof. Simon Best as Interim Chief Executive Officer, effective immediately.

    Read Article
  • Prometic to initiate PBI-4050 pivotal phase 3 clinical trial in Alström Syndrome

    Prometic to initiate PBI-4050 pivotal phase 3 clinical trial in Alström Syndrome

    The protocol for the Phase 3 clinical trial will be designed to meet expectations from both the U.S and EU regulatory agencies.

    Read Article
  • Prometic provides corporate update

    Prometic provides corporate update

    This includes a significant reduction in the Corporation’s cash use in 2019, driven by significant growth in its bioseparation revenues & a reduction of anticipated R&D expenditures by up to $30m.

    Read Article
  • Prometic reports third quarter 2018 financial results and highlights

    Prometic reports third quarter 2018 financial results and highlights

    Implementation of cost control measures to significantly reduce operational burn and extend cash runway

    Read Article
  • loading
    Loading More...